CAPTRUST Financial Advisors
CAPR icon

CAPTRUST Financial Advisors’s Capricor Therapeutics CAPR Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,190
Closed -$4K – 4944
2022
Q1 		$4K Buy
+1,190
New +$4.69K ﹤0.01% 4234

Other funds holding CAPR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAPTRUST Financial Advisors's CAPR Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of Capricor Therapeutics (CAPR) in Q2 2022, closing a stake of 1,190 shares — an estimated $4K sold.

CAPTRUST Financial Advisors first reported a position in CAPR in Q1 2022 and held it in 1 quarter. The position peaked at $4K in Q1 2022. 29 funds tracked by Wall St. Rank hold CAPR as of Q2 2022.

  • CAPTRUST Financial Advisors reported no remaining Capricor Therapeutics position as of Q2 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 1,190 Capricor Therapeutics shares in Q2 2022, an estimated $4K.
  • CAPTRUST Financial Advisors first reported a position in Capricor Therapeutics in Q1 2022 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Capricor Therapeutics position peaked at $4K in Q1 2022.
  • 29 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.